Diagnostic Effectiveness of Virtual Bronchoscopy
Learn more about:
Related Clinical Trial
Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia.
Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator
PR3-AAV Resilient Remission or PRRR
Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)
Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA
Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis
Hydroxychloroquine in ANCA Vasculitis Evaluation
Vasculitis Illness Perception (VIP) Study
Reproductive Health in Men and Women With Vasculitis
Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis
Impact of Vasculitis on Employment and Income
Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
VCRC Tissue Repository
Yellow Fever Vaccine in Patients With Rheumatic Diseases
Journey of Patients With Vasculitis From First Symptom to Diagnosis
One-Time DNA Study for Vasculitis
Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.
Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
The ANCA Vasculitis Questionnaire (AAV-PRO©)
Vasculitis Pregnancy Registry
VCRC Patient Contact Registry Patient-Reported Data Validation Study
Educational Needs of Patients With Systemic Vasculitis
Diagnostic Effectiveness of Virtual Bronchoscopy
Alemtuzumab for ANCA Associated Refractory Vasculitis
Interventional Cryotherapy for the Eradication of Benign Airway Disease (“ICE the BAD”)
PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis
BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis
RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides
Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides
Rituximab Vasculitis Maintenance Study
Anti-Cytokine Therapy for Vasculitis
Rituximab and Belimumab Combination Therapy in PR3 COMBIVAS
American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis
Low-dose Glucocorticoid Vasculitis Induction Study
Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis
Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides
Plasma Exchange for Renal Vasculitis
PRO Development for ANCA Associated Vasculitis
Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study
Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.
The Assessment of Prednisone In Remission Trial (TAPIR) – Patient Centric Approach
Steroids and Methotrexate to Treat Systemic Vasculitis
Efficacy Study of Two Treatments in the Remission of Vasculitis
Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography
The Assessment of Prednisone In Remission Trial – Centers of Excellence Approach
Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis
A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis
Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)
Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener’s) and Microscopic Polyangiitis
Mycophenolate Mofetil for Treatment of Relapses of Wegener’s Disease or Microscopic Polyangiitis (MPA)
Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener’s)
Rituximab for the Treatment of Wegener’s Granulomatosis and Microscopic Polyangiitis
Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides
Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis.
An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener’s Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies
Etanercept to Treat Wegener’s Granulomatosis
Treatment of Wegener’s Granulomatosis With Cyclophosphamide
Mycophenolate Mofetil to Treat Wegener’s Granulomatosis and Related Vascular Inflammatory Conditions
Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener’s Granulomatosis
Comparison of Treatments to Maintain Disease Remission in Patients With Wegener’s Granulomatosis and Related Vasculitis Syndromes
Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener’s Granulomatosis)
Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease NoAAC PR-03 Study
Analysis of Bronchial Tissue and Fluid in Patients With Wegener’s Granulomatosis
TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis
Cardiovascular Involvement in Patients With Granulomatosis With Polyangiitis
An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis
Daclizumab to Treat Wegener’s Granulomatosis
Study of One Protein Implicated in Wegener Disease
Abatacept in Treating Adults With Mild Relapsing Wegener’s Granulomatosis
Phase II Study on Gusperimus in Patients With Refractory Wegener’s Granulomatosis
Etanercept for Wegener’s Granulomatosis
Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener’s Granulomatosis